论文部分内容阅读
目的:探索晚期非小细胞肺癌(NSCLC)中ERCC1和Survivin对铂类化疗疗效的预测价值。方法:96例晚期NSCLC患者经免疫组化(IHC)检测ERCC1和Survivin的表达,患者行至少2周期含铂方案化疗,2周期化疗后评价疗效,分析疗效与免疫组化表达状态间关系。结果:ERCC1和Survivin在肿瘤组织中阳性表达率分别为58.3%(56/96)和76.0%(73/96)。ERCC1阴性组化疗有效率和1年生存率均高于阳性组(Ρ<0.05);Survivin阴性组化疗有效率和1年生存率高于阳性组,但无统计学意义(Ρ>0.05)。COX回归分析发现ERCC1阳性患者的死亡风险是阴性患者的3.390倍。结论:ERCC1和Survivin在NSCLC高表达,其中ERCC1与其化疗疗效及预后有关。
Objective: To explore the predictive value of ERCC1 and Survivin in the treatment of platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC). Methods: The expression of ERCC1 and Survivin in 96 patients with advanced non-small cell lung cancer (NSCLC) was detected by immunohistochemistry (IHC). The patients were treated with at least 2 cycles of platinum-containing regimen. The efficacy was evaluated after 2 cycles of chemotherapy and the relationship between therapeutic effect and immunohistochemistry was analyzed. Results: The positive rates of ERCC1 and Survivin in tumor tissues were 58.3% (56/96) and 76.0% (73/96), respectively. The effective rate of chemotherapy and 1-year survival rate of ERCC1-negative group were higher than that of the positive group (P <0.05). The Survivin-negative group’s chemotherapy efficiency and 1-year survival rate were higher than those of the positive group, but there was no statistical significance (P> 0.05). COX regression analysis found that ERCC1-positive patients were 3.390 times more likely to die than patients who were negative. Conclusion: ERCC1 and Survivin are highly expressed in NSCLC, of which ERCC1 is related to the efficacy and prognosis of chemotherapy.